Selma Atalay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Selma Atalay has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Elke M. G. J. de Jong
Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands
5 shared publications - Juul M. P. A. van Den Reek
Department of Dermatology Radboud University Medical Centre Nijmegen the Netherlands
5 shared publications - Peter Cornelis Maria van de Kerkhof
Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands
3 shared publications - Wietske Kievit
Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publications - Alfons Abigael Den Broeder
Department of Rheumatology, Sint Maartenskliniek , Nijmegen
2 shared publications - Hans Groenewoud
Department for Health Evidence Radboud University Nijmegen the Netherlands
2 shared publications
Latest Publications
- Open Access
- 1 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (6) , 1028-1030
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
- 1 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (6) , 1028-1030
Open AccessRegaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
- Open Access
- 23 February 2022
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (5) , 2680-2684
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatment, and lower risks and cost...
- 23 February 2022
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (5) , 2680-2684
Open AccessSerum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatment, and lower risks and cost...
- Open Access
- 28 March 2021
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 8 (2) , 163-172
Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
Background Personal treatment goals have been systematically investigated in psoriasis patients with active but not in controlled disease. Objectives To explore patient needs in psoriasis patients with controlled disease due to biologic therapy with adalimumab, etanercept or ustekinumab. Methods Treatment needs in patients on adalimumab, etanercept or ustekinumab with a stable low disease activity for ≥ 6 months and preferably a Psoriasis Area and Severity Index (PASI) < 5, were explored with the Patient Needs Questionnaire (PNQ). Goal importance was expressed as overall mean importance score, percentage of patients that reported a goal to be quite/very important, and per PNQ subscale. Data were analysed separately for treatment, gender, age group (< 50 vs. ≥ 50 years), biologic naivety and willingness to participate in a pragmatic dose-reduction strategy. Results Sixty-five patients were included. ‘To be free of itching’, ‘to be healed of all skin defects’ and ‘to have confidence in the therapy’ were rated quite/very important in 78.5% of the patients, followed by ‘to have no fear the disease will progress’ (75.4%) and ‘to get better skin quickly’ (75.4%). Goals related to the subscale ‘confidence in healing’ were still of high importance in controlled disease. Least importance was attributed towards social goals. For female patients, it was significantly more important than for males to ‘feel less depressed’ and ‘be comfortable showing yourself more in public’. Conclusions Psoriasis patients with controlled disease still report substantial treatment needs, with high importance ascribed to confidence in healing. To apply personalized medicine, treatment needs should be explored on an individual level.
- 28 March 2021
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 8 (2) , 163-172
Open AccessUnmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
Background Personal treatment goals have been systematically investigated in psoriasis patients with active but not in controlled disease. Objectives To explore patient needs in psoriasis patients with controlled disease due to biologic therapy with adalimumab, etanercept or ustekinumab. Methods Treatment needs in patients on adalimumab, etanercept or ustekinumab with a stable low disease activity for ≥ 6 months and preferably a Psoriasis Area and Severity Index (PASI) < 5, were explored with the Patient Needs Questionnaire (PNQ). Goal importance was expressed as overall mean importance score, percentage of patients that reported a goal to be quite/very important, and per PNQ subscale. Data were analysed separately for treatment, gender, age group (< 50 vs. ≥ 50 years), biologic naivety and willingness to participate in a pragmatic dose-reduction strategy. Results Sixty-five patients were included. ‘To be free of itching’, ‘to be healed of all skin defects’ and ‘to have confidence in the therapy’ were rated quite/very important in 78.5% of the patients, followed by ‘to have no fear the disease will progress’ (75.4%) and ‘to get better skin quickly’ (75.4%). Goals related to the subscale ‘confidence in healing’ were still of high importance in controlled disease. Least importance was attributed towards social goals. For female patients, it was significantly more important than for males to ‘feel less depressed’ and ‘be comfortable showing yourself more in public’. Conclusions Psoriasis patients with controlled disease still report substantial treatment needs, with high importance ascribed to confidence in healing. To apply personalized medicine, treatment needs should be explored on an individual level.
- Open Access
- 7 January 2021
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (3) , 1591-1597
Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice
Tightly-controlled dose reduction was possible during 1 year in psoriasis patients on adalimumab, etanercept or ustekinumab with low disease activity (CONDOR trial). Extended observation is needed ...
- 7 January 2021
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (3) , 1591-1597
Open AccessTwo-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice
Tightly-controlled dose reduction was possible during 1 year in psoriasis patients on adalimumab, etanercept or ustekinumab with low disease activity (CONDOR trial). Extended observation is needed ...
- Open Access
- 1 December 2020
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 100 (19) , adv00340
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who ...
- 1 December 2020
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 100 (19) , adv00340
Open AccessHealth Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who ...
- Open Access
- 8 May 2017
- Published by Springer Nature in BMC Dermatology
- Vol. 17 (1) , 6
Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial
Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic therapies became available in the last 10 years. Data from patients with rheumatoid arthritis revealed that dose tapering combined with tight control of disease activity is successful. For psoriasis patients the lowest effective dose of biologics needs to be determined. The objective was to assess whether dose tapering of biologics guided by Psoriasis Area and Severity Index (PASI) and Dermatology Quality of Life Index (DLQI) scores in psoriasis patients with controlled disease activity is non-inferior (NI) to usual care. This is a multicenter, pragmatic, randomized, non-inferiority trial with cost- effectiveness analysis. One hundred and twenty patients with stable low disease activity (PASI ≤ 5 and DLQI ≤ 5) for at least 6 months with a stable use of adalimumab, etanercept or ustekinumab will be randomized 1:1 to the dose reduction group or usual care. In the dose reduction group, the treatment intervals will be prolonged stepwise, resulting in a 33% and 50% dose reduction, respectively. Disease activity is monitored every three months with PASI and DLQI. In case of flare the treatment is adjusted to the previous effective dose. The primary outcome (PASI) at 12 months will be analyzed with ANCOVA in which the baseline PASI will be included as covariate to gain efficiency. The secondary outcomes include number of and time to disease flares, health-related quality of life, serious adverse events, and costs. With this study we want to assess whether disease activity guided dose reduction of biologics can be achieved for psoriasis patients with low stable disease activity, without losing disease control. By using the lowest effective dose of biologics, we expect to minimize side effects and save costs. This trial was registered at ClinicalTrials.gov ( NCT 02602925 ). Trial registration date October 9 2015.
- 8 May 2017
- Published by Springer Nature in BMC Dermatology
- Vol. 17 (1) , 6
Open AccessTight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial
Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic therapies became available in the last 10 years. Data from patients with rheumatoid arthritis revealed that dose tapering combined with tight control of disease activity is successful. For psoriasis patients the lowest effective dose of biologics needs to be determined. The objective was to assess whether dose tapering of biologics guided by Psoriasis Area and Severity Index (PASI) and Dermatology Quality of Life Index (DLQI) scores in psoriasis patients with controlled disease activity is non-inferior (NI) to usual care. This is a multicenter, pragmatic, randomized, non-inferiority trial with cost- effectiveness analysis. One hundred and twenty patients with stable low disease activity (PASI ≤ 5 and DLQI ≤ 5) for at least 6 months with a stable use of adalimumab, etanercept or ustekinumab will be randomized 1:1 to the dose reduction group or usual care. In the dose reduction group, the treatment intervals will be prolonged stepwise, resulting in a 33% and 50% dose reduction, respectively. Disease activity is monitored every three months with PASI and DLQI. In case of flare the treatment is adjusted to the previous effective dose. The primary outcome (PASI) at 12 months will be analyzed with ANCOVA in which the baseline PASI will be included as covariate to gain efficiency. The secondary outcomes include number of and time to disease flares, health-related quality of life, serious adverse events, and costs. With this study we want to assess whether disease activity guided dose reduction of biologics can be achieved for psoriasis patients with low stable disease activity, without losing disease control. By using the lowest effective dose of biologics, we expect to minimize side effects and save costs. This trial was registered at ClinicalTrials.gov ( NCT 02602925 ). Trial registration date October 9 2015.